Home » Stocks » SEEL

Seelos Therapeutics, Inc. (SEEL)

Stock Price: $0.961 USD -0.009 (-0.93%)
Updated December 2, 4:00 PM EST - Market closed
After-hours: $0.980 +0.019 (1.99%) Dec 2, 5:59 PM

Stock Price Chart

Key Info

Market Cap 51.33M
Revenue (ttm) n/a
Net Income (ttm) -23.31M
Shares Out 46.99M
EPS (ttm) -0.61
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 2
Last Price $0.961
Previous Close $0.970
Change ($) -0.009
Change (%) -0.93%
Day's Open 0.943
Day's Range 0.902 - 1.020
Day's Volume 705,974
52-Week Range 0.420 - 1.560

More Stats

Market Cap 51.33M
Enterprise Value 43.43M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 46.99M
Float n/a
EPS (basic) -0.58
EPS (diluted) -0.61
FCF / Share -0.48
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 481,819
Short Ratio 1.08
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 8.22
Revenue n/a
Operating Income -23.24M
Net Income -23.31M
Free Cash Flow -22.70M
Net Cash 7.91M
Net Cash / Share 0.15
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -121.91%
ROE -273.59%
ROIC 512.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$8.00*
(732.55% upside)
Low
4.00
Current: $0.961
High
12.00
Target: 8.00
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue0.38---4.849.262.517.953.604.97
Revenue Growth-----47.74%268.74%-68.4%120.51%-27.55%-
Gross Profit0.38---3.928.34-0.123.711.751.03
Operating Income-29.75-3.18-10.68-13.67-21.35-22.61-17.62-25.26-15.53-21.40
Net Income-51.26-3.480.32-7.43-19.02-21.79-16.94-31.77-18.12-29.51
Shares Outstanding20.313.080.400.220.170.130.110.090.070.04
Earnings Per Share-2.52-1.130.81-34.50-114.91-165.02-147.02-348.04-270.03-747.08
Operating Cash Flow-19.31-1.58-10.47-13.07-22.64-18.02-15.07-14.38-9.72-6.89
Capital Expenditures----0.02-0.33-0.583.08-0.44-0.26-0.44
Free Cash Flow-19.31-1.58-10.47-13.08-22.97-18.60-11.98-14.82-9.98-7.33
Cash & Equivalents10.260.046.332.094.1711.6921.7415.187.499.75
Total Debt-2.44-6.659.404.782.603.414.004.53
Net Cash / Debt10.26-2.406.33-4.56-5.236.9119.1411.773.495.22
Assets11.100.196.714.707.7814.8123.3123.8816.6218.86
Liabilities11.104.902.3412.2217.7312.8912.3417.2611.807.30
Book Value-0.01-4.714.37-7.52-9.941.9210.976.624.8211.57
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Seelos Therapeutics, Inc.
Country United States
Employees 8
CEO Raj Mehra

Stock Information

Ticker Symbol SEEL
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SEEL

Description

Seelos Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing and commercializing of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorder and post-traumatic stress disorder; SLS-005, a protein stabilizer for the treatment of Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.